44 research outputs found
Avaliação dos potenciais evocados auditivos do tronco encefĂĄlico na esclerose mĂșltipla
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.consensus development conferencejournal articlepractice guidelineresearch support, non-u.s. gov't2015 Jul 142015 06 19importe
Acute hemorrhagic leukoencephalitis mimicking herpes simplex encephalitis: case report
Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
RecomendaçÔes quanto ao uso de drogas imunomoduladoras na esclerose mĂșltipla: o consenso do BCTRIMS
Consenso brasileiro para o tratamento da esclerose mĂșltipla : Academia Brasileira de Neurologia e ComitĂȘ Brasileiro de Tratamento e Pesquisa em Esclerose MĂșltipla
O crescent arsenal terapĂȘutico na esclerose mĂșltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do ComitĂȘ Brasileiro de Tratamento e Pesquisa em Esclerose MĂșltipla e do Departamento CientĂfico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que Ă© melhor para cada paciente, com base em evidĂȘncias e prĂĄticas atualizadas. Por meio deste documento, propomos recomendaçÔes prĂĄticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratĂ©gias de tratamento na EM.The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS